Perry Genova, PhD
Dr. Genova is President & CEO of Oncoscope, Inc., a medical device company in RTP, NC developing a groundbreaking cancer diagnostic. Perry joined Oncoscope in September 2009 and developed strategic, product and clinical development, and fund raising plans. Additionally, Dr. Genova recruited a medical advisory panel, and formulated strategies and planning for regulatory approval, adoption, and reimbursement. Perry also supports regional entrepreneurial initiatives by engaging in activities which include teaching, mentoring and advising. Examples of such initiatives include the NC Kickstart at UNC Chapel Hill, The Mentor, FastTrac TechVenture™2009 in the Research Triangle Park-NC, and the NCSU TECH Program at the North Carolina State University.
Prior to reconnecting with his entrepreneurial roots, Perry served as Vice President and Dose Form Leader for Metered Dose Inhalers with GlaxoSmithKline in Evreux, France. In this role he was responsible for pro-actively managing the manufacturing systems for the MDI dose form by integrating his team into the drug development process, ensuring comprehensive technical understanding of the drug products. This process was well aligned with QbD, PAT and MDI technical strategies which he developed for the MDI dose form.
From 1996 through 2006 Dr. Genova was Vice President of Biomedical Engineering at Kos Pharmaceuticals where he built an integral part of Kos’ lung delivery franchise, ultimately valued at $800MM. In this role, Dr. Genova was responsible for enabling the burgeoning aerosol program by supporting ongoing R&D, creating unique delivery system solutions, assessing the competitive landscape and developing an overall corporate inhalation franchise strategy.
From 2002 he served as the Project Team Leader for Kos’ Inhaled Insulin program. Dr. Genova has authored over 30 scientific papers and presentations and has received 20 US patents to date. He has also been principally involved in a number of successful startup ventures and is very proud of his key role and relationship with Quill Medical which was acquired by Angiotech Pharma in 2006 for $US 200 million. His earlier venture, IEP, was acquired by Kos Pharmaceuticals in 1999. Kos was acquired subsequently by Abbott in 2006 for $US 3.6 billion while the valuation of the aerosol program was approximately $US 800 million.
Prior to joining Kos, Dr. Genova was employed by the medical school at UNC – Chapel Hill where he instructed and mentored graduate level students in human movement analysis research. Of particular interest to Dr. Genova were his research programs exploring human movement through Chaos Theory. As it turns out, Dr. Genova’s experience with chaos has proven to be quite enabling during his tenure within the pharmaceutical industry! Dr. Genova began his career in pharma with ER Squibb & Sons where he was responsible for the development of research instrumentation and device programs. He joined Glaxo, Inc. in the early 90’s to develop similar support functions within R&D.
Perry and his wife Jean presently reside in Chapel Hill, NC where they are raising two beautiful children – Madeline and Lucien. Perry spends his free time restoring and racing vintage BMW automobiles. By aligning his passion for motorsports with his technical acumen, he has built a global brand and following around his innovative engineering designs and technical developments.
Back to Board of Directors page...
Prior to reconnecting with his entrepreneurial roots, Perry served as Vice President and Dose Form Leader for Metered Dose Inhalers with GlaxoSmithKline in Evreux, France. In this role he was responsible for pro-actively managing the manufacturing systems for the MDI dose form by integrating his team into the drug development process, ensuring comprehensive technical understanding of the drug products. This process was well aligned with QbD, PAT and MDI technical strategies which he developed for the MDI dose form.
From 1996 through 2006 Dr. Genova was Vice President of Biomedical Engineering at Kos Pharmaceuticals where he built an integral part of Kos’ lung delivery franchise, ultimately valued at $800MM. In this role, Dr. Genova was responsible for enabling the burgeoning aerosol program by supporting ongoing R&D, creating unique delivery system solutions, assessing the competitive landscape and developing an overall corporate inhalation franchise strategy.
From 2002 he served as the Project Team Leader for Kos’ Inhaled Insulin program. Dr. Genova has authored over 30 scientific papers and presentations and has received 20 US patents to date. He has also been principally involved in a number of successful startup ventures and is very proud of his key role and relationship with Quill Medical which was acquired by Angiotech Pharma in 2006 for $US 200 million. His earlier venture, IEP, was acquired by Kos Pharmaceuticals in 1999. Kos was acquired subsequently by Abbott in 2006 for $US 3.6 billion while the valuation of the aerosol program was approximately $US 800 million.
Prior to joining Kos, Dr. Genova was employed by the medical school at UNC – Chapel Hill where he instructed and mentored graduate level students in human movement analysis research. Of particular interest to Dr. Genova were his research programs exploring human movement through Chaos Theory. As it turns out, Dr. Genova’s experience with chaos has proven to be quite enabling during his tenure within the pharmaceutical industry! Dr. Genova began his career in pharma with ER Squibb & Sons where he was responsible for the development of research instrumentation and device programs. He joined Glaxo, Inc. in the early 90’s to develop similar support functions within R&D.
Perry and his wife Jean presently reside in Chapel Hill, NC where they are raising two beautiful children – Madeline and Lucien. Perry spends his free time restoring and racing vintage BMW automobiles. By aligning his passion for motorsports with his technical acumen, he has built a global brand and following around his innovative engineering designs and technical developments.
Back to Board of Directors page...